| abstract |
Claim 1: A pharmaceutical combination comprising a QDC inhibitor selected from the compounds of the formula (1), wherein Ar is a phenyl group, which is unsubstituted or substituted by 1, 2, or 3 identical or different substituents selected from: halogen; nitro, cyano, C1-4 alkyl, trifluoromethyl, hydroxyl or C1-4 alkoxy; or a pharmaceutically acceptable salt or solvate thereof; and a compound capable of inhibiting the kinase activity of the epidermal development factor receptor (RFDE). Claim 7: The pharmaceutical combination according to claim 1, wherein the compound capable of inhibiting the kinase activity of the epidermal development factor receptor (RFDE) is selected from erlotinib or lapatinib. Claim 10: The pharmaceutical combination according to claim 1; wherein said combination also includes gemcitabine. |